Research and Technology
Scitech believes that trust in its products
With this commitment, we are dedicated to developing clinical studies based on ethical and scientific principles and in accordance with the National and International Standards and Regulations applied to Clinical Research.
Additionally, we recognize the importance of transparently presenting the clinical research that is conducted with our devices. Thus, our studies are registered on official public research platforms such as ClinicalTrials.gov.
|Inspiron I Study||Multicenter, prospective, randomized study to evaluate safety and efficacy of Inspiron Sirolimus Eluting Stent (NCT01093391)||LINK||60||5 years||Completed / Published|
|Destiny Trial||Multicenter, prospective, randomized study to show non-inferiority of Inspiron Sirolimus Eluting Stent against Biolimus Eluting Stent (NCT01856088)||LINK||170||5 years||Completed / Published|
|Inspiron Real Life Registry||Investigator initiated, prospective, non-randomized study to demonstrate the performance of Inspiron Sirolimus Eluting Stent in complex population||LINK||470||3 years||Completed / Published|
|Inspiron Real Life II Registry||Multicenter, prospective, non-randomized registry to demonstrate the performance of Inspiron Sirolimus Eluting Stent in real-world population (NCT03263260)||LINK||5000||2 years||Ongoing|
|Inspiron Repair||Multicenter, prospective, randomized study to evaluate the tissue coverage after Inspiron Sirolimus Eluting Stent implantation at 1, 2 and 3 months (NCT03269461)||LINK||60||2 years||Ongoing|
|Inspiron All-commers||Prospective, non-randomized, single center study to evaluate clinical outcomes after Inspiron stent implantation||LINK||790||12 months||Completed / Published|
|Inspiron Latitude||Multicenter, prospective, non-randomized registry to demonstrate the performance of Inspiron Sirolimus Eluting Stent in real-world population (NCT03471234)||LINK||500||2 years||Ongoing|
|Embosoft I||Multicenter, prospective, non-randomized study to evaluate the uterine volume reduction and quality of life improvement after Uterine Artery Embolization for leyomioma treatment (NCT03535610)CT03535610)||LINK||30||6 months||Ongoing|
|Solaris I||Multicenter, prospective, non-randomized study to evaluate the performance of the Solaris Vascular Stent Graft on the treatment of obstructive iliac artery disease||LINK||50||2 years||Ongoing|